Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor-Mutant Lung Cancer

In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine. Clin Cancer Res; 16(22); 5371-3. (C) 2010 AACR.